StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Progress on a Phase IIb trial at a major US site (Yale) plus international sites improves pipeline visibility and potential future regulatory milestones; although data readouts are not yet disclosed, the expansion reduces execution risk and can support a re-rating if results are favorable.
What happened, with direct paths to the underlying reporting
SciSparc said NeuroThera has launched the Phase IIb portion of SCI-110 at Yale, expanding trials to Hannover and Tel Aviv. Phase IIa demonstrated a 21% average tic reduction on the Yale Global Tic Severity Scale, underpinning the Phase IIb design. Positive data or faster enrollment could lift SPRC's CNS pipeline valuation in coming quarters.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.